crohn's disease
"Was in remission when I began entyvio, within 90 days I began to become jaundice, it caused severe problems with my eyesight even having bile drain from tear ducts, massive bile fluid retention, changes in liver function, unexplained abscesses, acute disease progression requiring hospitalizations, corrective surgeries. Since I have discovered new safety guidelines have been released which Takeda pharmaceutical hid, and failed to inform patients or doctors that fistulizing patients are NOT suitable candidates for this drug, and as of Dec 2016, the maker and the FDA have not made this information public as company stock would plummet. 
This drug is extremely dangerous and was fast tracked by the FDA due to the companies financial crisis.."